TICKERNERD
Menu
CTMXCTMXHealthcare · Biotechnology

CTMX Stock Forecast: CytomX Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 2 Oct 2026
$2.56
−2.66% on the day

The 8 Wall Street analysts covering CytomX Therapeutics, Inc. hold a median 12-month price target of $12 — +368.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 48 of 100 as at 2 Oct 2026 — in the lower half.

Market cap
$557.8M
Ticker Nerd rank
48 / 100
Median analyst target
$12
Analysts covering
8
Revenue$1.4M−92.4% y/y
Operating income−$23.8M
Net income−$20.7M
Free cash flow−$18.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−5.2%
1M
−31.2%
YTD
−39.9%
1Y
−22.0%
From 52W high
−62.1%
From 52W low
0.0%
$2.56
$6.75
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CTMX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores CytomX Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 2 Oct 2026
48 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
71
Revisions
70
Value
66
Momentum
64
Size
52
Issuance
37
Accruals
35
Volatility
25
Growth
17

Quality (71): The business earns solid, repeatable profits on what it owns.

Growth (17): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CTMX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CTMX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00Jan 26Apr 26Jul 26Oct 26CTMXHigh $16Median $12Low $6

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says8 analysts
8 Buy0 Hold0 Sell
Low $6Median $12High $16

The green dot is the last close — the median target sits +368.8% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 0 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
13 Aug 2026JP MorganMaintainsOverweight$12 → $11
10 Aug 2026GuggenheimMaintainsBuy$15 → $14
11 May 2026HC Wainwright & Co.MaintainsBuy$17 → $11
11 May 2026HC Wainwright & Co.MaintainsBuy—
23 Mar 2026Piper SandlerMaintainsOverweight—
19 Mar 2026BarclaysMaintainsOverweight—
18 Mar 2026GuggenheimMaintainsBuy—
18 Mar 2026JefferiesMaintainsBuy—
17 Mar 2026WedbushMaintainsOutperform—
16 Mar 2026HC Wainwright & Co.MaintainsBuy—
16 Mar 2026JP MorganUpgradeOverweight—
9 Mar 2026GuggenheimReiteratesBuy—
4 Feb 2026BarclaysMaintainsOverweight—
4 Feb 2026Cantor FitzgeraldMaintainsOverweight—
20 Jan 2026BarclaysMaintainsOverweight—
20 Jan 2026GuggenheimInitiatesBuy—
20 Jan 2026Piper SandlerMaintainsOverweight—
11 Nov 2025HC Wainwright & Co.MaintainsBuy—
21 Oct 2025BarclaysMaintainsOverweight—
22 Sept 2025Cantor FitzgeraldInitiatesOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CTMX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

CTMX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 2 Oct 2026, CytomX Therapeutics, Inc. returned −22.0% against +16.2% for the S&P 500, dividends included.

CTMX vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160180Jan 26Apr 26Jul 26Oct 26CTMXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CTMX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
4
Analysts cutting
1
Fundamentals

CytomX Therapeutics, Inc. (CTMX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
15.9×

Cheaper than 43% of US stocks

Price / sales
30.5×

Cheaper than 7% of US stocks

Price / book
1.8×

Cheaper than 47% of US stocks

EV / EBITDA
−2.7×

Cheaper than 75% of US stocks

Growth & margins
Revenue growth (YoY)
−92.4%

Higher than 2% of US stocks

Earnings growth (YoY)
−92.4%

Higher than 3% of US stocks

Gross margin
—
Operating margin
−1677.1%

Higher than 4% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−37.8%

Higher than 25% of US stocks

Return on assets
−19.6%

Higher than 20% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

CytomX Therapeutics, Inc. (CTMX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • CytomX Therapeutics, Inc. has a market value of $557.8M and an enterprise value of $233.2M.

  • Revenue in the twelve months to 30 June 2026: $18.3M. The latest quarter shrank 92.4% year on year.

  • Net income over the same four quarters: −$79.7M, a −435.2% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$82.5M.

  • Shares outstanding: 217.9M.

  • Trailing P/E: 15.9×; forward P/E: −5.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • CytomX Therapeutics, Inc. employs 69 people — $265K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 3 Oct 2026

Data provided by Twelve Data

Peers

CTMX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CTMXCytomX Therapeutics, Inc.$557.8M
48
SGMTSagimet Biosciences, Inc.$559.2M
37
CRMDCorMedix, Inc.$560.4M
58
MPLTMapLight Therapeutics, Inc.$545.8M
11
PHATPhathom Pharmaceuticals, Inc.$541.8M
74
PRMEPrime Medicine, Inc.$540.5M
39
YDESYD Bio Ltd.$574.5M
2

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own CytomX Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CTMX news & analysis

CytomX Therapeutics, Inc. (CTMX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Seeking Alpha · 14 Sept 2026neutral

CytomX Therapeutics presented at the Morgan Stanley 24th Annual Global Healthcare Conference, and a transcript of the presentation was published by Seeking Alpha. The item reports on the company's participation and remarks at the conference.

Why it matters — The presentation gives CTMX watchers direct insight into the company's updates and messaging delivered to investors at a major healthcare conference.

CytomX Therapeutics to Present at Upcoming September Investor Conferences

GlobeNewsWire · 1 Sept 2026neutral

CytomX Therapeutics announced that its management will participate in several investor conferences scheduled for September. The announcement outlines upcoming conference appearances but provides no other details.

Why it matters — The conference presentations could raise visibility for CytomX among investors and provide updates on its masked, conditionally activated biologics platform.

CytomX Therapeutics Announces FDA Fast Track Designation for Varsetatug masetecan (“Varseta-M”) for Relapsed/Refractory Metastatic Colorectal Cancer (R/R mCRC)

GlobeNewsWire · 27 Aug 2026positive

CytomX Therapeutics announced that the FDA has granted Fast Track Designation to Varseta-M for the treatment of patients with relapsed/refractory metastatic colorectal cancer. The designation follows encouraging Phase 1 data, and a potential Varseta-M monotherapy registrational study in R/R mCRC is planned to begin in the first half of 2027.

Why it matters — Fast Track Designation for Varseta-M could help expedite development of a lead candidate for an area of unmet need, and CTMX watchers will track the planned 2027 registrational study.

CytomX Therapeutics: Promising Varseta-M With Comfortable Runway

Seeking Alpha · 12 Aug 2026positive

A Seeking Alpha article discusses CytomX Therapeutics' PROBODY platform and its lead asset Varseta-M, noting early colorectal cancer activity but stressing the need for larger and more mature datasets. It highlights upcoming data catalysts, including a Varseta-M monotherapy update, combination-study data, and new gastrointestinal cohorts through the first half of 2027.

Why it matters — A CTMX watcher would care because the article outlines several near-term pipeline catalysts from Varseta-M and the PROBODY platform that could shape the company's outlook.

CytomX Therapeutics, Inc. (CTMX) Q2 2026 Earnings Call Transcript

Seeking Alpha · 7 Aug 2026neutral

CytomX Therapeutics held its Q2 2026 earnings call, and Seeking Alpha published a transcript of the event. The excerpt contains only the headline and attribution identifying the transcript's availability.

Why it matters — The Q2 2026 earnings call transcript provides CTMX watchers with direct insight into the company's latest quarterly results and management commentary.

FAQ

Frequently asked questions about CTMX stock

What is the CTMX stock price forecast for 2026-2027?

The 8 Wall Street analysts covering CytomX Therapeutics, Inc. have a median 12-month price target of $12, with estimates ranging from $6 to $16. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CTMX stock a buy right now?

Of the 8 analysts covering CytomX Therapeutics, Inc., 8 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks CytomX Therapeutics, Inc. 48 out of 100 across roughly 4,600 US stocks as at 2 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CTMX?

As at 2 Oct 2026, CytomX Therapeutics, Inc. ranks 48 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (71 of 100).

Will CTMX stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts implies +368.8% from the last close, and Ticker Nerd's factor model ranks CytomX Therapeutics, Inc. 48 out of 100 as at 2 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CTMX stock forecast for 2030?

No analyst covering CytomX Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CTMX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6 to $16 over the next 12 months.

How has CTMX stock performed over the past year?

CytomX Therapeutics, Inc. returned -22.0% over the 12 months to 2 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does CytomX Therapeutics, Inc. do?

CytomX Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on oncology.

What is the latest news on CTMX?

The most recent item we track (Seeking Alpha, 14 Sept 2026): "CytomX Therapeutics, Inc. (CTMX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript". CytomX Therapeutics presented at the Morgan Stanley 24th Annual Global Healthcare Conference, and a transcript of the presentation was published by Seeking Alpha. The item reports on the company's participation and remarks at the conference.

Company

About CytomX Therapeutics, Inc.

CytomX Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on oncology. The company develops conditionally activated biologics through its Probody therapeutic platform, with the goal of localizing activity to the tumor microenvironment and limiting effects on healthy tissue. Its current pipeline spans multiple cancer-focused modalities, including antibody-drug conjugates, T-cell engagers, and immune-modulating therapies such as cytokines. CytomX Therapeutics also advances programs aimed at difficult-to-treat tumors, supporting research and development across a range of solid-tumor indications. Headquartered in South San Francisco, California, CytomX Therapeutics plays a specialized role in the biotechnology market as a developer of targeted cancer therapeutics designed for precision and selectivity.

CEO Dr. Sean A. McCarthy DPHIL · 69 employees · United States · https://www.cytomx.com